Articles tagged with Hormone Therapy
A two-year study found that testosterone therapy normalised testosterone levels, reduced NAFLD, and suppressed symptoms of hypogonadism in obese men. Testosterone therapy may help obese men with functional hypogonadism and type-2 diabetes reduce the prevalence of non-alcoholic fatty liver disease.
A study of 100 transgender adolescents found that gender-affirming hormone therapy does not increase cardiovascular disease risk. The treatment was associated with reduced symptoms of gender dysphoria and improved mental health outcomes.
Researchers at UVA Cancer Center have unveiled new insights into how hormones known as androgens act on cells, which could lead to improved treatments for prostate, ovarian, and breast cancers. The study found that a complex signaling system regulates androgen receptor activity, using an enzyme called Parp7.
A study identified a tumor marker that can predict which breast cancer patients will benefit from early HER2 targeted therapy, helping to avoid disease relapse. The research found that low or absent MLH1 and PMS2 gene expression may indicate an increased risk of death from the disease.
A Phase 1 study of Z-endoxifen in patients with solid tumors reported partial responses in three patients and prolonged stable disease in eight. The study suggests that Z-endoxifen can benefit patients who have progressed on tamoxifen treatment, particularly those with desmoid tumors.
A study of 92 adolescents found that girls are more likely to develop high blood pressure and dyslipidemia associated with obesity. The researchers believe personalized treatment is needed due to differences in hormone and neuropeptide profiles between girls and boys, regardless of weight and age.
Researchers aim to identify adrenal insufficiency in sepsis patients before glucocorticoid therapy. The study's findings suggest that supplementing glucocorticoids may not be necessary or beneficial for all patients, potentially leading to improved patient outcomes.
Researchers enrolled 50 Black and 50 white men with advanced prostate cancer to test hormone therapy abiraterone acetate plus prednisone. They found that Black men's PSA levels dropped further and more frequently, but disease progression and survival times were similar.
Fertility concerns significantly affect young women with hormone receptor-positive breast cancer treatment decisions, new research shows. Women who express fertility concerns are more likely to choose not to start or discontinue endocrine therapy.
Researchers at Dartmouth's Norris Cotton Cancer Center have found that cycling between estrogen treatment and anti-estrogen therapies can dramatically increase the duration of tumor regression in mice. This unconventional approach suggests treating short-term with estrogen before resistance occurs, leading to better long-term control.
A small proportion of women with anti-estrogen treatment after breast cancer surgery have worse outcomes due to mutations in the estrogen receptor gene. Research found that 1% of breast cancer cases already at initial diagnosis have these resistant mutations, leading to poorer response to hormonal treatment and higher risk of recurrence.
A Monash University study has discovered a way to prevent and reverse the damage caused by broken-heart syndrome, also known as Takotsubo cardiomyopathy. The breakthrough uses Suberanilohydroxamic acid to target genes and improve cardiac health.
Researchers summarize growing knowledge on light therapy's mechanism, effectiveness, and applications in treating neurodegenerative diseases like Alzheimer's and Parkinson's. Light stimulation has been shown to restore memory and cognition, improve sleep quality, and reduce symptoms in patients with these conditions.
A study found that gender-affirming hormone therapy can lead to changes in blood pressure among transgender men and women, with an average decrease in systolic blood pressure for women and increase for men. The study highlights the importance of monitoring blood pressure and preventive measures in this patient population.
Researchers at CU Cancer Center have discovered that tumor-suppressing genes MAP3K7 and CHD1 deletion increases androgen receptor signaling, making patients less responsive to anti-androgen therapy. This knowledge could lead to personalized treatment approaches for men with aggressive prostate cancer.
Researchers confirmed the molecular classification's predictive value for treatment benefits in advanced hormone-sensitive breast cancer. The study found that different subtypes responded differently to ribociclib and other treatments.
A Phase 1 study of Z-endoxifen in patients with solid tumors demonstrated antitumor activity and prolonged stable disease, even in those who had previously responded sub-optimally to tamoxifen. The trial found that 44.4% of patients at certain dose levels achieved partial responses or stable disease.
A new treatment for late-stage neuroendocrine tumors has been shown to be more effective and have fewer side effects than the current standard of care. Researchers found that a modified therapy, known as 177Lu-DOTA-EB-TATE, is safest and produces the best tumor response when given in specific doses.
Researchers at Duke University Medical Center identified a key reason hormone therapies fail and proposed a new treatment strategy directly targeting the cancer's fuel source, glutamine. By inhibiting glutamine utilization, tumor growth is successfully inhibited in studies using prostate cancer cell lines and animal models.
Researchers found that hormone drugs can disrupt key receptors required for viral invasion of cells, blocking entry and replication. Anti-androgen therapies have shown promising results in treating COVID-19 infections, particularly among men with higher androgen levels.
Researchers found that combination therapy is equally effective to levothyroxine in treating hypothyroidism, with patients preferring DTE over other treatments. Desiccated thyroid extract (DTE) was shown to improve symptoms and lead to modest weight loss compared to levothyroxine.
A study by The Endocrine Society finds oral testosterone therapy undecanoate (TU) is an effective treatment for men with low testosterone levels, with a safety profile consistent with non-oral products. TU has minimal effects on cholesterol levels and no liver toxicity was reported.
Scientists develop patented RNA-based therapy to degrade overexpressed PMP22 protein, restoring nerve function and strength in mice. The treatment uses biocompatible siRNA nanoparticles and controls particle size and injection amount.
Decision theory enhances treatment choices by considering multiple possibilities in contradictory diagnostic findings, as shown in a study of 3753 breast cancer patients. The approach outperformed conventional statistics, providing more accurate results and improving patient outcomes.
A $1.06 million grant has been awarded to LSU Health New Orleans School of Medicine to explore a new treatment for Castrate Resistant Prostate Cancer (CPRC). The research focuses on the role of Prostate Derived ETS Transcription Factor (PDEF) in prostate cancer, with the goal of identifying novel targets for intervention.
Researchers at EPFL successfully modeled ILC using a xenograft approach that simulates the tumor with high accuracy. The model reveals unique characteristics of ILC biology, including LOXL1's role in tumor progression.
Researchers identified two distinct pathways leading to septic shock, involving bioactive Adrenomedullin (bio-ADM) and Dipeptidyl peptidase 3 (DPP3). Early diagnosis with biomarker-guided approaches shows promising results in personalized medicine for sepsis treatment. New diagnostics are available for rapid detection of these biomarkers.
A study published by The Endocrine Society found that testosterone therapy increases the risk of blood clots, heart attack, and stroke in transgender men. Over 11% of participants developed erythrocytosis, a condition characterized by excessive red blood cells.
A new genomic test helps oncologists determine which patients with recurrent prostate cancer may benefit from hormone therapy, guiding precision medicine efforts. The Decipher test, measuring tumor gene activity, predicts risk of metastasis and death, even after adjusting for other factors.
A retrospective study found that melatonin significantly improved the median overall survival of prostate cancer patients with poor prognosis, reducing mortality risk by more than twice. The antitumor effects of melatonin are fully realized in treating PCa patients with unfavorable tumor progression factors.
A randomized clinical trial found that endocrine therapies can reduce estradiol levels in men with hormone receptor-positive breast cancer after three months of treatment. The study suggests a potential new approach for male breast cancer patients.
A new imaging test can reliably distinguish breast cancer patients who are unlikely to benefit from hormone therapy. The test measures estrogen receptor functionality, and a PET scan detects increased progesterone receptors in response to estrogen stimulation.
Researchers have found that androgen receptor activation by natural androgens or a new drug has potent anti-tumour activity in all estrogen receptor positive breast cancers, even those resistant to current treatments. This study provides new evidence for an alternative treatment strategy.
Researchers found that surgery in addition to treatments like chemotherapy and radiation therapy increased survival for stage four breast cancer patients. Patients with hormone receptor-positive tumors saw a prolonged length of survival when their treatment plan included surgery.
Researchers found that surgery in addition to treatments like chemotherapy and radiation therapy increased the length of survival for stage four breast cancer patients. The study, published in Annals of Surgical Oncology, suggests that knowing a cancer's biological subtype can help determine effective treatment plans.
Researchers found that oral hormone therapy alters the metabolome of postmenopausal women, with estrogen-alone therapy providing a protective effect against cardiovascular disease. The study also identified metabolites associated with increased CHD risk in combination therapy.
ReceptorNet, a deep-learning algorithm developed by Salesforce Research, can determine hormone-receptor status from inexpensive tissue images, improving treatment decision-making for breast cancer patients. This technology has the potential to make high-quality therapies more accessible globally.
For older patients with hormone receptor-positive breast cancer, omitting postoperative radiation therapy did not compromise survival or increase risk of distant metastasis. Local recurrence rates were higher in those who didn't receive radiation therapy.
A recent study published in the British Journal of Sports Medicine found that transgender women may still retain a competitive advantage in athletic performance even after more than 12 months of hormone therapy. The study, which reviewed fitness test results and medical records of 29 trans men and 46 trans women, suggests that governin...
Research suggests stress hormones and immune cells may contribute to tumor recurrence by reactivating dormant cancer cells. Targeting stress hormones with approved drugs like beta-blockers could potentially prevent tumors from returning.
SWOG Cancer Research Network members will share results of five network-led studies at SABCS, advancing breast cancer science and medicine. The research includes findings from RxPONDER, a trial that may change practice in breast cancer treatment.
Researchers from the University of Vienna used high-resolution mass spectrometry to analyze environmental toxin interactions with therapeutics. The study found that exposure to substances like BPA and genistein can alter drug efficacy, leading to reduced effectiveness in cancer treatment and other conditions.
The menopause transition is a time of increasing heart disease risk for women, with significant changes in cardiometabolic and vascular health occurring during this phase. Early intervention strategies, such as hormone therapy and lifestyle modifications, are crucial to maintaining healthy heart function and reducing cardiovascular risk.
A new study published in eLife suggests that Lipocalin-2, a hormone produced by bone cells, could be used to treat people with obesity. The hormone has been shown to suppress food intake and increase feelings of fullness in mice and non-human primates.
High levels of GIP are linked to an increased risk of early arteriosclerosis signs, while GLP-1 is associated with a lower risk. The study suggests a potential link between raised GIP levels and cardiovascular disease in diabetic patients, highlighting the need for further investigation.
Researchers found that CRYM protein binds to hormone T3 and blocks cell membrane formation, inhibiting tumour growth. Lower CRYM levels are associated with poor prognosis.
A new medication has been shown to reduce the risk of heart failure-related events in patients with reduced ejection fraction. The study found that omecamtiv mecarbil, a novel heart medicine, had a greater effect on patients with lower ejection fractions.
Researchers at Michigan State University have identified a potential genetic target for treating an especially painful and invasive form of endometriosis. They discovered that targeting super-enhancers, altered by a mutation in the ARID1A gene, could lead to effective treatment using epigenetic therapy.
A randomized clinical trial demonstrated the reliability of using circulating tumor cell count to guide frontline therapy choice for patients with estrogen receptor-positive (ER+) HER2-negative (HER2) metastatic breast cancer. The CTC count significantly improved progression-free survival for patients with high CTC counts, while hormon...
A new study published in The BMJ provides updated estimates of the increased risks of breast cancer associated with hormone replacement therapy (HRT) use. For longer-term HRT use, the increased risks are lower than previously reported, while a more pronounced decline in risk is observed once HRT has stopped.
A University of Cincinnati biologist found that even small concentrations of estrogen in water can lead to a gender ratio imbalance and smaller fish populations. The study used least killifish, which have live young, and found that exposure to estrogen resulted in more females than males.
Researchers at Kanazawa University discovered that thymoquinone selectively kills prostate cancer cells with a SUCLA2 gene deletion. This finding offers a promising therapeutic option for advanced prostate cancer patients who have developed resistance to hormone therapy.
A new genetic test identifies patients with invasive lobular carcinoma (ILC) at high risk of recurring and progressing. The 70-gene signature test showed that ILC patients whose genetic make-up puts them at high risk may benefit from additional adjuvant therapy.
A recent study shows that most older women with breast cancer can safely undergo surgery, reducing the gap in survival rates between older and younger women. The research found that surgery is generally well-tolerated and offers slightly lower survival rates for those who don't have it.
A new study confirms hormone therapy reduces biomarkers of inflammation in postmenopausal women, with greatest benefits seen in those nearing menopause. The study suggests hormone therapy may slow progression of atherosclerosis by targeting inflammatory processes.
Fetal estrogens, such as estetrol and estriol, show promising characteristics in reducing hot flashes and improving cardiovascular health. They may also provide added benefits that have yet to be fully explored, making them a promising new approach to hormone therapy.
Recent advances in nonhormone therapy provide women with more options for managing hot flashes. The new treatments target the KNDy neuron complex, which is activated during menopause, resulting in hot flashes. These innovations include drugs developed for pain control and mood disorders acting via KNDy.
A recent study found that COVID-19 can lead to lower testosterone levels in male patients, which may explain the better outcomes seen in female patients. The study also showed that hypogonadism, or low testosterone production, was present in over half of the male patients.
Human intestinal organoids grown from stem cells help identify peptide YY as a possible therapeutic for severe malabsorption. The hormone allows 80% of mice to survive with just one injection per day, showing promise for treating congenital disorder.
The European Society of Endocrinology reviews evidence on hormone involvement in COVID-19 infection, disease severity, and treatment. Obesity, cardiovascular disease, and sex hormones are identified as risk factors.